key: cord-0872549-xf2vi0vd authors: Abdoli, Amir; Falahi, Shahab; Kenarkoohi, Azra title: COVID-19-associated opportunistic infections: a snapshot on the current reports date: 2021-08-23 journal: Clin Exp Med DOI: 10.1007/s10238-021-00751-7 sha: 44eaa61556f23e0d723ad881b6f0204b1e087657 doc_id: 872549 cord_uid: xf2vi0vd Treatment of the novel Coronavirus Disease 2019 (COVID-19) remains a complicated challenge, especially among patients with severe disease. In recent studies, immunosuppressive therapy has shown promising results for control of the cytokine storm syndrome (CSS) in severe cases of COVID-19. However, it is well documented that immunosuppressive agents (e.g., corticosteroids and cytokine blockers) increase the risk of opportunistic infections. On the other hand, several opportunistic infections were reported in COVID-19 patients, including Aspergillus spp., Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci (carinii), mucormycosis, Cytomegalovirus (CMV), Herpes simplex virus (HSV), Strongyloides stercoralis, Mycobacterium tuberculosis, and Toxoplasma gondii. This review is a snapshot about the main opportunistic infections that reported among COVID-19 patients. As such, we summarized information about the main immunosuppressive agents that were used in recent clinical trials for COVID-19 patients and the risk of opportunistic infections following these treatments. We also discussed about the main challenges regarding diagnosis and treatment of COVID-19-associated opportunistic infections (CAOIs). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10238-021-00751-7. Coronavirus The Coronavirus Disease 2019 (COVID-19) was emerged in Wuhan, China, in late 2019 and immediately spread to become pandemic [1, 2] . The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has diverse sequels in all ages [3, 4] . However, older individuals (> 60 years old), males, and patients who have comorbidities or coinfections, such as pulmonary diseases, chronic kidney disease, diabetes, hypertension, and cardiovascular diseases, have a higher risk of severe infection [1, 2, 5, 6] . Close contact and respiratory droplets are the main route of COVID-19 transmission through breathing, sneezing, coughing, and even normal speech [7] [8] [9] . Pulmonary system is the most commonly affected organ, and therefore, the main clinical manifestations of COVID-19 are respiratory signs, including cough, dyspnea, sore throat, and fever [10] . In the severe COVID-19 state, development of pneumonia with acute respiratory distress syndrome (ARDS), hypoxic respiratory failure, and/or death have been occurred. On the other hand, extrapulmonary organ involvement (e.g., cardiac, neurologic, endocrine, gastrointestinal, hepatic, renal, ocular, and dermatologic) associated with loss of smell or taste has significant health threat [10, 11] . Mutations have been occurred in all viruses, including SARS-CoV-2 over time. While most mutations have scanted or no influence on the viruses' properties, some mutations may influence on the virus's properties, such as speed of spread, disease severity, performance of vaccines, diagnostic tools, therapeutic medicines, or other public health measures (https:// www. who. int/ en/ activ ities/ track ing-SARS-CoV-2varia nts/). Accordingly, three classes of SARS-CoV-2 variants were developed, including variants of concern (VOC) (B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and P.1 (Gamma)), variants of interest (VOI) (B.1.525 (Eta), B.1.526 (Iota), B.1.617.1 (Kappa) and C.37 (Lambda)), and variant of high consequence (VOHC)). VOC has increase transmissibility, severity of disease, reduced effectiveness of diagnosis, treatment, and vaccination. VOI has an increased prevalence rate. There is no VOHC till now. Evidence suggests that VOHC has the following properties, including failure diagnostics, significant reduction in vaccine effectiveness, reduced susceptibility to approved therapeutics, and more severe clinical disease and hospitalization rate (https:// www. cdc. gov/ coron avirus/ 2019-ncov/ varia nts/ varia nt-info. html# Conse quence). There are some differences between the symptoms of the new variants of SARS-CoV-2 with the typical symptoms of COVID-19. For instance, the symptoms of the Delta variant in the UK were akin to a heavy cold; instead, the typical symptoms of the COVID-19, such as loss of taste and smell and shortness of breath, were less prevalent [12] . Hyperinflammation and cytokine storm syndrome (CSS) are among the major causes of acute respiratory distress syndrome (ARDS), multiorgan failure, and death due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [13] [14] [15] . An unexpected increase in the circulating levels of proinflammatory cytokines, especially interleukin-1 (IL-1), IL-6, gamma interferon (IFNγ) and tumor necrosis factor-α (TNF-α), leads to hyperinflammation and the CSS [16] . When CSS occurs, different immune cells (e.g., neutrophils, macrophages, and T cells) infiltrate into the site of infection, and consequently, a cascade of damage of the vascular barrier, diffuse alveolar damage and lung injury, multiorgan failure, and ultimately death occurs [17] . ARDS is one of the major consequences of CSS that directly link to severe sequel and mortality in acute COVID-19 patients [13, 16] . Therefore, therapeutic strategies to mitigate the risk of CSS and ARDS are essential. Immunosuppressive therapy has been used to mitigate hyperinflammation and cytokine storm syndrome (CSS) in COVID-19 patients [18] . Administration of dexamethasone among hospitalized patients with COVID-19 resulted in lower 28-day mortality in patients who received oxygen or invasive mechanical ventilation [19] . The results of a recent meta-analysis revealed that administration of systemic corticosteroids (e.g., dexamethasone, hydrocortisone, and methylprednisolone) was associated with lower 28-day all-cause mortality compared with usual care or placebo [20] . Other studies reported the usefulness of Janus kinase (JAKs) inhibitors and inflammatory cytokine blockers, including IL-6, IL-1, TNFα, and granulocyte-macrophage colony-stimulating factor (GM-CSF) for CSS in COVID-19 patients (Table 1) . Taken together, immunosuppressive therapy has shown to have an important therapeutic option for patients with severe COVID-19. Immunosuppressive therapy has been used for a number of autoimmune diseases to alter their immune status (Supplementary Table 1 ). However, it is an important risk factor for opportunistic infection [21, 22] . Previous studies among patients with Inflammatory Bowel Disease (IBD) revealed that the use of corticosteroids, infliximab, and azathioprine/6-mercaptopurine was significantly increased the odds of opportunistic infection (OR = 3.4, OR = 4.4, and OR = 3.1, respectively) [22] . As reviewed elsewhere, a number of opportunistic pathogens (e.g., Aspergillus spp., Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci (carinii), mucormycosis, Cytomegalovirus (CMV), Herpes simplex virus (HSV), Strongyloides stercoralis, Mycobacterium tuberculosis, and Toxoplasma gondii) have been reported from patients who received immunosuppressive therapy for their underlying diseases, such as IBD, systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) [21] (Table 2) . The increased case reports of opportunistic infections in COVID-19 patients raise an important concern, especially for patients with underlying diseases and who received immunosuppressive therapy. Among the opportunistic infections, fungal infections account for the most case reports in COVID-19 patients. Other reported pathogens were related to viral, bacterial, protozoa, and helminth infections (Fig. 1 ). This narrative review is a snapshot about the main opportunistic infection among COVID-19 patients. Fungal infections are among the major infections among immunocompromised patients [23] . A sharp increase in the incidence and mortality rates of fungal infections has been reported among COVID-19 patients, especially those who received immunosuppressive therapies or who have underlying conditions [24] [25] [26] [27] [28] . Aspergillosis is caused by a common mold, Aspergillus spp., that lives indoors and outdoors. Most people are exposed to Aspergillus spores and breathe them every day without getting sick; however, individuals with compromised immune systems or lung diseases have a higher risk of developing active infection [23, 29, 30] . Until the emergence of COVID-19, a number of cases with COVID-19-associated pulmonary aspergillosis (CAPA) have been reported worldwide [31] [32] [33] [34] [35] [36] . Invasive pulmonary aspergillosis (IPA) is associated with high mortality rates among COVID-19 patients [37, 38] . The results of a multicentric retrospective cohort in France revealed that the overall mortality rate among COVID-19 patients with and without IPI was 71.4% versus 36.8%, p < 0.01. Treatment with azithromycin as well as with high-dose dexamethasone (which both of them have immunomodulatory properties) increased susceptibility to IPA among COVID-19 patients [39] . According to a recent review [31] , data from 186 cases of CAPA were gathered worldwide. The data revealed that 97.8% (182) JAKs: Janus kinases, IL: Interleukin, TNF-α: tumor necrosis factor-α, GM-CSF: granulocyte-macrophage colony-stimulating factor Drug names Corticosteroids [20] Dexamethasone [19, 184] Hydrocortisone [20] Methylprednisolone [20] JAKs inhibitors [200] Ruxolitinib [195] [196] [197] Baricitinib [198, 199] Tofacitinib [200] Tocilizumab [185, 186, 213] Anakinra [203, 204] Canakinumab [205, 206] TNF-α blockers Infliximab [201, 202] Mavrilimumab [207] 21.5%), and hematologic or oncologic disease (21; 11.3%) [31] . Collectively, the most important risk factors of CAPA were reported corticosteroid use and the presence of comorbidities [31, 38, 39] . Unfortunately, there is not an optimal diagnostic algorithm for diagnosing CAPA until now [38] . The most promising diagnostic modality for CAPA was included recovery of Aspergillus spp. on culture media of bronchoalveolar fluid (BALF) and tracheal aspirate and conventional Galactomannan (GM) testing from BALF [38] . Utilizing Aspergillus PCR and serologic biomarker testing are also useful and sensitive diagnostic tests for CAPA [38] . The first-line treatment of IPA is the approved drug voriconazole. Posaconazole is also approved for prophylaxis against invasive fungal infections [40] . Among the CAPA, patients who received voriconazole had a higher survival rate [35] . However, drug-drug interactions are the major challenge of voriconazole in the ICU setting [38, 41, 42] . Other treatments such as mold-active triazole and amphotericin B (AmB) have been used for CAPA as well [37] . Taken together, early diagnosis and treatment are the major challenges of aspergillosis among COVID-19 patients. Candida spp. is the second most numerous fungal infection worldwide [23] . The fungi are normally living on the skin, as well as inside the body, such as the throat, mouth, gut, and vagina. Oropharyngeal candidiasis is one of the most common infections in immunocompromised people, such as HIV/AIDS. Invasive candidiasis and candidemia are a serious and common infection in hospitalized patients (https:// www. cdc. gov/ fungal/ disea ses/ candi diasis/ invas ive/ index. html). C. albicans is the most common Candida species; however, the emerging species such as C. auris is a highly invasive and multidrug-resistant yeast causing complicated conditions [43, 44] . COVID-19-associated candidiasis (CAC) has been reported in a number of cases until now [43] , and C. auris was the most [214, 215] , meningitis [216, 217] , disseminated infection [218] , pneumonia [219] Pneumocystis jiroveci (carinii) pneumonia [220, 221] Aspergillosis [222] [223] [224] [225] Candidiasis: oral candidiasis [226] , esophageal candidiasis [227] , disseminated [228] Mucormycosis: pulmonary [229, 230] , disseminated [230] , cutaneous [231, 232] , gastric perforation [233] , maxillary sinus [234] Strongyloidiasis: Severe [235] [236] [237] [238] , disseminated [239, 240] , cerebral involvement [239] , pulmonary strongyloidiasis [241] , hyperinfection [242] Tuberculosis (pulmonary) [243] Cytomegalovirus (CMV) infection [244, 245] Toxoplasmosis: ocular toxoplasmosis [154] [155] [156] , cerebral toxoplasmosis [157, 158] JAKs inhibitors Toxoplasmosis: cerebral toxoplasmosis [159] , toxoplasmic retinitis [160] Cryptococcosis: pneumonia and pulmonary infection [246] [247] [248] , meningoencephalitis [249] , meningitis [250] Aspergillosis: retinal necrosis [251] Tuberculosis (pulmonary) [252] [253] [254] [255] CMV retinitis [256] IL-6 blockers Cryptococcosis: disseminated [190] , meningitis [191] Aspergillosis [192] Tuberculosis (pulmonary) [194] CMV pneumonitis [193] Toxoplasmosis: toxoplasmic retinochoroiditis [161, 162] , cerebral toxoplasmosis [163] Cryptococcosis: pneumonia and pulmonary infection [258, 259] , disseminated infection [260, 261] , meningitis [262, 263] , cutaneous infection [264] Pneumocystis jiroveci (carinii) pneumonia [265] [266] [267] [268] Aspergillosis: allergic bronchopulmonary [269] , pulmonary [270] , sinus aspergillosis [271] , central nervous system aspergillosis [272] , disseminated [273] Candidiasis: systemic candidiasis [274] , arthritis [275] , oral candidiasis [276] Mucormycosis: cutaneous [277] , gastric perforation [233] , disseminated [278] , sinusitis [279] , pulmonary [280] Strongyloidiasis: hyperinfection [281] Tuberculosis (pulmonary) [282] [283] [284] CMV retinitis [285] , disseminated CMV [286] IL-17A blockers (Ixekizumab) Toxoplasmosis: lymphadenopathy [164] reported species [43, [45] [46] [47] [48] . Other reported Candida species were C. albicans, C. tropicalis, C. parapsilosis, C. orthopsilosis, and C. glabrata among COVID-19 patients [43, 49] . The coinfection of C. auris and COVID-19 in critically ill patients has been related to an above 50% mortality rate [50, 51] . Prolonged ICU stay, central venous catheters, and corticosteroid use were among the major risk factors for candidiasis in COVID-19 patients [43] . The diagnosis of invasive candidiasis remains challenging, mainly due to the low number of Candida in infected tissues or circulation [43] . Serologic tests with β-D-Glucan (BDG) and mannan antigen as well as molecular platforms are recommended tests for diagnosis of candidiasis [52] [53] [54] . In COVID-19 patients, the treatment of invasive candidiasis is similar to that of non-COVID-19 patients [43] . Echinocandins that are usually well tolerated are the choice drugs for invasive candidiasis, while voriconazole, fluconazole, liposomal amphotericin B, posaconazolem, and isavuconazole are the second line of treatment [43] . Early diagnosis and treatment of CAC are important for management of the disease; however, multidrug-resistant species are a major challenge for CAC management. Mucormycosis is an invasive fungal infection caused by species belonging to Mucorales. Classically, immunosuppressive conditions such as uncontrolled diabetes mellitus (DM), neutropenia, and corticosteroid therapy are the major risk factors for mucormycosis [55] . Inhalation of spores is the main route of infection that usually causes pulmonary infection; however, cutaneous and soft tissue invasion primarily occurs after skin disruption because of traumatic injuries, surgery, or burns [55] . Rhino-orbito-cerebral infection classically develops in patients with uncontrolled DM. Gastrointestinal mucormycosis is a rare manifestation of the infection, which is mostly reported in neonates [55] . The mortality rates of mucormycosis varied from 40 to 80%, depending on the site of infection and underlying conditions [55] . The global prevalence of mucormycosis is ranging from 0.005 to 1.7 per million, while its prevalence is about 0.14 per 1000 in India [56, 57] . Diabetes mellitus, ketoacidosis, hematological malignancies, glucocorticoid use, or broad-spectrum antibiotics, transplantation, prolonged neutropenia, trauma, iron overload, illicit intravenous drug use, Fig. 1 A snapshot on the CAOIs. Created by https:// www. canva. com/ neonatal prematurity, and malnourishment are among the main predisposing factors of mucormycosis [58, 59] . Diagnosis of mucormycosis consists of clinical diagnosis, imaging modalities alongside with histopathology, cultures, and molecular techniques [59] . High-dose liposomal amphotericin B is the first-line treatment of mucormycosis, while isavuconazole (intravenous) and posaconazole (intravenous or delayed release tablets) are recommended with moderate strength [55] . COVID-19-associated mucormycoses (CAM) have been reported in a number of cases worldwide [60] [61] [62] [63] . According to a recent systematic review, 101 cases (82 cases from India and 19 from the rest of the world) of CAM have been reported worldwide till now [60] . The infection was predominantly reported in males (78.9%) and in COVID-19 patients who had active (59.4%) or recovered (40.6%) infection. The most common clinical presentation of CAM was invasive infection in the nose and sinuses (88.9%), followed by rhino-orbital (56.7%) involvement. Preexisting DM was recorded in 80% of the cases, and corticosteroid therapy was seen in 76.3% of cases. The mortality rate was 30.7% of the cases [60] . The general management for mucormycosis included hyperglycemia control, early treatment with liposomal amphotericin B, and surgery [62] , although treatment with amphotericin B and isavuconazole had only about 50% clinical improvement in CAM cases (reviewed in [58] ). The major challenge of CAM is the late diagnosis of the disease and consequently treatment failure. Hence, early diagnosis of mucormycosis is of utmost importance in COVID-19 patients. Cryptococcus neoformans is an encapsulated yeast that causes subclinical infection in immunocompetent individuals. Humans can become infected by breathing fungal spores, and so, pulmonary infection is the major form of the disease. Corticosteroid or immunosuppressive therapy, DM, and malignancies are among the major risk factors of cryptococcosis [64] . Severe infections, cryptococcemia, meningoencephalitis, and pulmonary cryptococcosis have been reported in immunocompromised patients [23, 64, 65] . Serologic methods based on antigen screening and advanced molecular methods are sensitive and specific tests for the diagnosis of cryptococcosis [66, 67] . Antifungal agents, including amphotericin B, fluconazole, and 5-flucytosine, are the current approved treatment of cryptococcosis [68] . Till now, some cases of Cryptococcus infection were reported in COVID-19 patients [65, 69, 70] , which one of them was a 60-year-old man who received tocilizumab plus corticosteroids and diagnosed with candidemia and cryptococcemia [65] . Despite antifungal therapy, the patient died within 10 days of cryptococcemia [65] . Meningoencephalitis due to C. neoformans was reported in a 73-year-old woman who received azithromycin and dexamethasone after COVID-19 infection [70] . Other cases were reported from COVID-19 patients with several underlying diseases who received immunosuppressive therapy (e.g., corticosteroids and tocilizumab) [24, [71] [72] [73] . Like other fungal infections, early detection and treatment can improve the outcome of infection in COVID-19 patients. Pneumocystis jirovecii is another common respiratory opportunistic pathogen in individuals with immunocompromising conditions, which causes pneumocystis pneumonia (PCP). PCP spreads from person to person through the air. Some healthy adults have the fungus in their lungs asymptomatically, and they can spread the infection to other individuals. The choice treatment for PCP is trimethoprim/ sulfamethoxazole (TMP/SMX), which also known as cotrimoxazole (https:// www. cdc. gov/ fungal/ disea ses/ pneum ocyst is-pneum onia/ index. html# sympt oms). Coinfection of PCP and COVID-19 has been reported in some patients with COVID-19 till now [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] , in which some of them received immunosuppressive therapies, such as corticosteroids [76, 81, 88, 89] and tocilizumab [88] . The first confirmed case of PCP and COVID-19 coinfection was diagnosed by autopsy and real-time PCR in a 52-year-old male chronic smoker and drinker with severe dyspnea. The patient and 17 h postdiagnosis [90] . Chong et al. [85] reviewed 12 cases of COVID-19 and PCP coinfection. Accordingly, all PCP infections were reported in critically ill patients with COVID-19, which most of them were immunosuppressed with HIV (58.3%, 7/12) or long-term exposure to immunosuppressants (91.7%, 11/12), such as high-dose corticosteroids. In both HIV and non-HIV patients, severe lymphocytopenia (< 1000 cells/ mm3) was encountered with absolute lymphocyte count (ALC) less than 900 and CD4 + T cell count less than 200 cells/mm. Another laboratory finding among coinfected patients was elevation of serum lactate dehydrogenase (LDH) and β-D-glucan. The diagnostic samples were lower respiratory tract (LRT) specimens, including sputum, BAL, and endotracheal aspirate (ETA). The diagnosis was made by microscopic staining, immunofluorescence microscopy (IFM), or molecular methods. Sulfamethoxazole-trimethoprim are the most used therapy of the patients. The mortality rate was 42.9% (3/7) in the HIV group and 40% in non-HIV group [85] . Diagnosis of COVID-19 and PCP coinfection is challenging because there are clinical and radiological similarities between the two diseases [90] , while, in some cases, PCP was misdiagnosed as COVID-19 in patients with underlying diseases [89, [91] [92] [93] [94] . In these cases, differential diagnosis by laboratory tests should be considered alongside with clinical and radiological findings. To date, scarce information is available regarding the coinfection of endemic fungal infections with CIVID-19. Histoplasmosis caused by Histoplasma capsulatum was reported in five cases of COVID-19 from Brazil [95] [96] [97] and Argentina [98, 99] in which three of them were HIV positive as well [96, 98, 99] . All cases had pulmonary infections and two of them developed disseminated histoplasmosis [98, 99] . All patients were successfully treated with the antifungal itraconazole. Pulmonary coccidioidomycosis caused by Coccidioides immitis was reported in three cases of COVID-19 from the US. The infection was occurred in two Hispanic males (48 and 52 years) [100, 101] and a 48-year-old Hispanic female [102] . Two of them received dexamethasone before developing coccidioidomycosis [101, 102] . A 52-year-old male was died before receiving antifungals [101] , while other two patients were treated with fluconazole that resulted in clinical improvement [100, 102] . Paracoccidioidomycosis coinfected with COVID-19 was reported in a 19-year-old Brazilian male with abdominal distension, disseminated cutaneous lesions, and multiple cervical, axillary, and inguinal lymph node enlargements [103] . The patient was treated with Amphotericin B lipid complex, but later developed a bloodstream infection that empirically received piperacillin-tazobactam [103] . Bacterial coinfections are associated with increased morbidity and mortality rates among patients with respiratory viral infections, including influenza and COVID-19 [104] [105] [106] . To date, numerous studies have been reported the association of COVID-19 with bacterial infections; many of them are classified as nosocomial or hospital-acquired infections. In this regard, the results of a living rapid review and metaanalysis revealed that bacterial coinfection and secondary bacterial infection were detected in 3.5% (95%CI 0.4-6.7%) and 14.3% (95%CI 9.6-18.9%) of COVID-19 patients, respectively. Critically ill patients reported to have more bacterial infection (8.1%, 95%CI 2.3-13.8%) [107] . A prospective cohort study analyzed data from 48 902 COVID-19 inpatients from 260 hospitals in England, Scotland, and Wales. The results have shown that the most common pathogens causing respiratory coinfections were Staphylococcus aureus and Haemophilus influenzae, which diagnosed ≤ 2 days after admission. S. aureus and Enterobacteriaceae were also the most common secondary respiratory infections. As such, the most frequent bloodstream infections were caused by Escherichia coli and S. aureus [108] . A retrospective study among 257 laboratory-confirmed COVID-19 patients in China (Jiangsu Province) revealed coinfection with 24 respiratory pathogens among the patients; Streptococcus pneumoniae, followed by Klebsiella pneumoniae and H. influenzae, was the most common bacterial coinfections [109] . A study among COVID-19 patients who admitted to ICU in Iran revealed that all patients had bacterial coinfections, including Acinetobacter baumannii (90%) and S. aureus (10%) strains. Antibiotics resistance was found in 17% of A. baumannii isolates. Methicillin-resistant S. aureus (MRSA) was detected in an isolate [110] . Mycoplasma pneumoniae, Pseudomonas aeruginosa, and Legionella pneumophila are other important bacterial pathogens that were detected among COVID-19 patients [104] . Tuberculosis (TB) remains as a significant public health problem worldwide. According to the estimations, a quarter of the world's human population has latent TB infection [111] . Like COVID-19, TB can spread through the air from an infected person to others. The primary site of TB infection is the lungs; however, extrapulmonary infection is common, especially among immunocompromised patients [112] . Coinfection of TB with COVID-19 has been reported in a number of studies [113] [114] [115] [116] [117] . There are some similarities between the clinical symptoms of TB and COVID-19; hence, misdiagnosis of both infections has been reported [118] . However, studies have shown that TB infection can worsen outcome of the COVID-19 disease, leading to increased severity and mortality [114] . According to a recent metaanalysis, coinfection of M. tuberculosis with SARS-CoV-2 infection resulted in two times increased risk of mortality among COVID-19 patients (RR = 2.10; 95% CI, 1.75-2.51; I2 = 0%) [119] . Hence, strategies for prevention, screening, and treatment of TB should be considered in patients who suspected to COVID-19 infection. Respiratory viral pathogens, including Influenza, Parainfluenza, Metapneumovirus, and Rhinovirus, were reported among COVID-19 patients in different studies [120] [121] [122] . However, some infections such as CMV and HSV are opportunistic pathogens that could reactivate after immunosuppression. CMV is a latent infection in immunocompetent individuals. The seroprevalence rate of CMV accounts about 80% in the elderly. CMV has been shown to manipulate the immune system by affecting T cell proliferation, decreasing in naïve T cell diversity, and increasing inflammatory cytokines (e.g., IL-6), leading to aging of the immune system (also called immunosenescence) [123, 124] . CMV infection has several sequels, mainly retinitis, pneumonitis, encephalitis/myelitis, neuropsychiatric disorder, and intrauterine infection [125] [126] [127] . Ganciclovir is an effective treatment option for CMV infection, especially for immunosuppressed individuals [128, 129] . To date, disseminated CMV infection [130] , CMV myocarditis [131] , CMV proctitis [132] , pneumonitis [133, 134] as well as CMV viremia [135, 136] were reported among COVID-19 patients, in which some of them received corticosteroids [130, [132] [133] [134] [135] [136] or tocilizumab [135] . While CMV is latent in most individuals, reactivation of latent infection can lead to severe infections with fatal outcomes following immunosuppression in COVID-19 patients. Therefore, differential diagnosis and treatment should be considered in these patients. HSV is a contagious virus that categorizes into two types, including HSV-1 or oral herpes and HSV-2 or genital herpes. HSV-1 is generally responsible for cold sores and fever blisters around the mouth and lips; it can also cause genital herpes in some cases. HSV-2 is primarily causing sores around the genitals or rectum. HSV can be transmitted by direct contact. HSV-1 is transmitted through contact with oral secretions or sores on the skin and HSV-2 during sexual intercourse [137] . Sensory neurons are the main targets of HSV. Both HSV-1 and HSV-2 establish latent infections, and reactivation occurs after stress or immunosuppression [137] . Aciclovir is the standard therapy for HSV infections, which helps symptom control, but it could not eliminate the latent infection [137] . Reactivation of latent HSV and CMV infections has been reported among COVID-19 patients [138] . Seeßle et al. [139] found a high rate of HSV-1 reactivation (83.3%, 15 out of 18 patients) in invasively ventilated COVID-19 patients. Encephalitis due to HSV-1 was reported in a 73-year-old woman who suspected to prior COVID-19 infection [140] . Conjunctivitis was also reported in a 69-year-old male with COVID-19 infection [141] . Five cases of HSV-1 keratitis were reported in COVID-19 patients in Slovakia [142] . Fatal cases of acute liver failure due to HSV-1 infection were reported in two COVID-19 patients following tocilizumab and methylprednisolone prescriptions [143] . Coinfection of HSV and HIV infection [144] as well as with HSV and varicella zoster virus (VZV) infections [145] was reported in critically ill patients with COVID-19. Varicella-like exanthem was reported among 22 patients with COVID-19 in Italy [146] . While HSV has diverse symptoms and sequels, differential diagnosis and management of the infection could mitigate the outcome of COVID-19 patients. Parasitic protozoa are a large group of unicellular pathogens, including blood and tissue protozoa (e.g., malaria, Leishmania, Toxoplasma, Trypanosoma, etc.) and intestinal and luminal protozoa (e.g., Entamoeba, Giardia, Cryptosporidium, Cyclospora, Blastocystis, Trichomonas vaginalis, etc.) [147] . However, intestinal protozoa and toxoplasmosis are an important opportunistic infections because their infections are usually latent or asymptomatic in healthy individuals, but severe infections could occur in immunocompromised patients [148, 149] . Reactivation of latent toxoplasmosis causes severe sequel in HIV/ AIDS and immunocompromised patients (see the next subtitle) [149] . Intestinal protozoa can modulate immune responses through their direct interaction with host cells or by changing the gut microbiome composition [147] . To date, scarce information is available regarding the interaction of intestinal protozoa and COVID-19. Hence, there is an opportunity for researchers to investigate about the interaction of intestinal protozoa and COVID-19 in the clinical setting and experimental models. Nevertheless, opportunistic protozoa infection should not be neglected among COVID-19 patients, especially in endemic regions and in tropical and subtropical areas. Like the latent CMV infection, toxoplasmosis is a latent infection in immunocompetent individuals, but reactivation of latent toxoplasmosis or acquired toxoplasmosis among immunocompromised patients can cause severe infections with various sequels, such as toxoplasmic encephalitis, disseminated infections, and death [150] [151] [152] [153] . Combination of pyrimethamine and sulfadiazine is the choice drug for toxoplasmosis treatment among nonpregnant women [149] . Reactivation of latent toxoplasmosis has been reported in a number of patients who received immunosuppressive therapy, such as corticosteroids [154] [155] [156] [157] [158] , JAKs inhibitors [159, 160] , TNF-α blockers [161] [162] [163] and IL-17A blockers [164] , and the most common sequels were ocular [154] [155] [156] [160] [161] [162] and cerebral [157] [158] [159] 163] toxoplasmosis. In a case-control study among 100 COVID-19 patients in Egypt, a significantly higher prevalence of toxoplasmosis was detected among mild to moderate COVID-19 patients than the healthy control group [165] . Indeed, T. gondii seropositive cases exhibited a significant increase in lymphocytic expression of programmed death-1 (PD-1), which is a marker that correlates with proinflammatory status. Due to the high prevalence rates of latent toxoplasmosis in humans, reactivation of latent infection should be considered following immunosuppressive therapy in COVID-19 patients [166] . Helminths are among the major neglected tropical diseases (NTDs) worldwide. Most of the helminth infections are causing chronic infections with minor clinical symptoms [167, 168] . Nevertheless, helminth infections could alter the immune system toward type 2 immunity and antiinflammatory conditions, leading to diminished the essential immune response against microbial pathogens and increased susceptibility and severity of infectious diseases [167] [168] [169] . Helminths can also cause malabsorption and compete for host nutrients [169] . Helminth infections can also mitigate vaccine efficacy by suppressing immune responses [169] . The outcome of COVID-19 patients may be worsened in individuals with helminth coinfections [169] [170] [171] . Further investigations are needed to demonstrate the interaction between helminths and SARS-CoV-2 infection. Strongyloidiasis is a neglected tropical infection caused by the soil-transmitted helminth Strongyloides stercoralis. Strongyloidiasis is usually asymptomatic in immunocompetent individuals, while disseminating infection and hyperinfection syndrome are important sequels among immunocompromised patients [172, 173] . The infected stage of the parasite is the filariform larva, which can penetrate into the human skin when it contacts with contaminated soil; then, the larva migrates to the small intestine and transforms to the adult worm. Alternatively, consumption of raw vegetables contaminated with filariform larva could be a source of infection. Internal autoinfection is common, leading to hyperinfection syndrome. Disseminated strongyloidiasis usually occurs in patients with immunocompromising conditions leading to complicated conditions [172, 173] . Ivermectin is the choice drug for treatment of strongyloidiasis; also, it could be used as a preventive strategy for high-risk populations (e.g., HIV/AIDS and immunocompromised individuals) [174] . Disseminated strongyloidiasis is reported in two patients with COVID-19 up until now [175, 176] , in which both of them received immunosuppressive agents (dexamethasone [176] , methylprednisolone, and tocilizumab [175] ). Therefore, patients who received immunosuppressive therapy are considered as a high-risk group and should be screened for S. stercoralis, especially in tropical areas in which the infection is high prevalence. Most of the opportunistic infections have no or at least minor clinical symptoms among immunocompetent individuals. Nevertheless, these infections have several sequels among immunocompromised patients, such as patients with cancer and malignancies [177] [178] [179] , organ recipients' individuals [180] , patients with autoimmunity who received immunosuppressive therapies [22] and HIV/AIDS patients with low CD 4 T cell counts [21, 181] . The CSS and ARDS are among the major causes of multiorgan failure and death due to COVID-19 [182, 183] . Hence, immunosuppressive therapy with corticosteroids [19, 20, 184] and monoclonal antibodies has been used to mitigate the CSS in critically ill COVID-19 patients ( Table 1 ). Administration of dexamethasone in hospitalized patients with COVID-19 resulted in a significant increase in the number of ventilator-free days [184] and a lower mortality rates [19] over 28 days. The results of a meta-analysis have shown that administration of systemic corticosteroids (e.g., dexamethasone, hydrocortisone, and methylprednisolone) in comparison with usual care or placebo was associated with in lower 28-day all-cause mortality [20] . Previous reports revealed that corticosteroid use increases the risk of different opportunistic infections ( Table 2) . A number of opportunistic infections have been reported among COVID-19 patients who received immunosuppressive therapies (Table 3) . For instance, CAPA and CAM were associated with corticosteroid use in 52.7% [31] and 76.3% [60] of COVID-19 patients, respectively. Tocilizumab is an IL-6 blocker that is used in a number of trials for COVID-19 patients [185] . The results of two randomized, double-blind, placebo-controlled trials revealed that tocilizumab was associated with a reduced likelihood of mechanical ventilation or death in hospitalized patients with COVID-19 [186] , but was not effective for prevention of intubation or death in moderately ill patients with COVID-19 [187] . The results of a metaanalysis demonstrated that administration of tocilizumab to standard therapy was associated with reduced need for mechanical ventilation and mortality rate in patients with severe COVID-19 [185] . IL-6 is produced in response to infections and tissue damage [188] , although IL-6 inhibition was associated with an increased risk of secondary bacterial and fungal infections [189] . Likewise, disseminated cryptococcosis [190] , meningitis [191] , invasive aspergillosis [192] , CMV pneumonitis [193] , and tuberculosis [194] were reported in patients who received tocilizumab (Table 2 ). In COVID-19 patients, different cases with cryptococcosis [24, 65, [71] [72] [73] , aspergillosis [88] , strongyloidiasis [175] , PCP [88] , CMV [135] , and HSV [143] infections were reported following tocilizumab use ( Table 3) . Inhibition of the JAKs pathway (ruxolitinib [195] [196] [197] , baricitinib [198, 199] , and tofacitinib [200] ), TNFα (infliximab [201, 202] ), IL-1 (Anakinra [203, 204] and Canakinumab [205, 206] ), and GM-CSF (Mavrilimumab [207] ) was also used for mitigating the CSS in COVID-19 patients (Table 1) . These immunomodulatory agents can also increase the risk of opportunistic infections (Table 2) , although there are not reported in COVID-19 patients till now. Some opportunistic infections are associated with alterations of the immune system, such as CMV [123] and helminth infections [167, 169] ; hence, coinfection with these pathogens could mitigate essential immune responses against SARS-CoV-2 and probably diminish the immune response following vaccination [169] . Early detection and differential diagnosis of opportunistic infections are an important point and challenging issue in COVID-19 patients. Early detection can lead to early treatment and consequently lower sequel and better outcome of COVID-19 patients. Differential diagnosis should be considered especially for opportunistic respiratory infections, such as PCP [89, [91] [92] [93] [94] . These infections could be misdiagnosed with COVID-19 in some cases due to some clinical and paraclinical similarities. In the COIVD-19 period, the diagnostic procedures are diverted to COVID-19. Although vigilance is needed in the diagnosis of COVID-19, the common disorders should not be negligible [208] . Reactivation of latent infection following immunosuppression is the major cause of severe infections in some opportunistic infections, such as HSV, CMV, TB, and toxoplasmosis [21, 149] . Prophylaxis with TMP-SMX can reduce the risk of some opportunistic infections, such as PCP, TB, toxoplasmosis, and different bacterial infections [21, 209, 210] . Hence, prophylactic strategies may be useful for COVID-19 patients, especially for those who received immunosuppressive therapy or who have underlying diseases. Drug-drug interaction is a challenge for treatment of opportunistic infections in COVID-19 patients, especially those who hospitalized in ICU [211] . For example, drug-drug interactions are the major challenge of voriconazole in the ICU setting [38, 41, 42] . Concentrations of itraconazole and clindamycin are increased by lopinavir/ritonavir, while voriconazole, posaconazole, and clarithromycin increase lopinavir/ritonavir concentration [212] . Hence, the possibility of drug-drug interaction should consider when prescribing new medications in COVID-19 patients. Mutations of the SARS-CoV-2 virus are an emerging challenge that could be associated with reduced effectiveness of diagnosis, treatment, and vaccination as well as increased transmissibility and severity of the disease (https:// www. cdc. gov/ coron avirus/ 2019-ncov/ varia nts/ varia nt-info. html# Conse quence). In these conditions, coinfection with opportunistic pathogens could be an additional challenge for the diagnosis, treatment, and management of COVID-19 patients. To date, some clinical studies are registered in the clinicaltrials.gov regarding opportunistic infections and COVID-19. However, it seems that future studies are needed for standard diagnosis and new treatment options of these infections in COVID-19 patients (Table 4) . Opportunistic infections Corticosteroids Aspergillosis [31, 88] Candidiasis [43] Mucormycosis [60] Cryptococcosis [24, 65, [71] [72] [73] Pneumocystis jiroveci (carinii) pneumonia [76, 81, 88, 89] Histoplasma capsulatum [95, 96, 98] Coccidioides immitis [101, 102] Strongyloidiasis [175, 176] CMV [130, 132, 135, 136] HSV [143] IL-6 blocker (Tocilizumab) Cryptococcosis [24, 65, [71] [72] [73] Pneumocystis jiroveci (carinii) pneumonia [88] Aspergillosis [88] Strongyloidiasis: [175] CMV: [135] HSV: [143] Limitations of the study In this review, we summarized the main opportunistic infections among COVID-19 patients. However, one of the major limitations of this review is lots of case reports or case series with various settings, diagnosis, and treatment strategies. Hence, if there was a systematic review article regarding opportunistic infections, we selected these articles instead of each case report. Taken together, the COVID-19 patients with underlying diseases or who received immunosuppressive therapy have an increased risk of CAOIs. Strategies for screening and early diagnosis, treatment, and prophylaxis could mitigate the risk of CAOIs in COVID-19 patients. Future investigations for generation of reliable algorithms and standardization of diagnostic procedures are highly needed for early and differential diagnosis of CAOIs in COVID-19 patients. As such, standard prophylactic strategies are needed in highrisk COVID-19 patients, such as those who received immunosuppressive therapy, patients with underlying diseases, patients who admitted to the ICU, and those who received invasive mechanical ventilation. The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s10238-021-00751-7. A novel coronavirus from patients with pneumonia in China Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet Sex and gender differences in the outcome of patients with COVID-19 Claims and reasons about mild COVID-19 infection in children Frequency of underlying diseases, symptoms and mortality rate of COVID-19: a systematic review and meta-analysis Prevalence and clinical presentation of COVID-19 infection in hemodialysis patients Transmission routes for SARS-CoV-2 infection: review of evidence COVID-19 reinfection: prolonged shedding or true reinfection? Hospital indoor air quality monitoring for the detection of SARS-CoV-2 (COVID-19) virus. Sci Total Environ Perisetti A. Pulmonary and extra-pulmonary clinical manifestations of COVID-19 Extrapulmonary manifestations of COVID-19 Lifting of COVID-19 restrictions in the UK and the Delta variant. The Lancet Respir Med COVID-19: consider cytokine storm syndromes and immunosuppression Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts COVID-19 infection: concise review based on the immunological perspective The COVID-19 cytokine storm; what we know so far. Front Immunol Immune responses to the novel coronavirus-2: Friend or Foe? Immunol Investig Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review Dexamethasone in hospitalized patients with Covid-19 Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis Opportunistic infections-coming to the limits of immunosuppression? Cold Spring Harbor Perspect Med Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology Human fungal infections Opportunistic fungal infection associated with COVID-19. Open Forum Infect Dis COVID-19 and fungal superinfection High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections Fungal infections in COVID-19-positive patients: a lack of optimal treatment options Invasive mould disease in fatal COVID-19: a systematic review of autopsies. The Lancet Microbe Aspergillus fumigatus and Aspergillosis in 2019 COVID-19-associated pulmonary aspergillosis Aspergillosis complicating severe coronavirus disease Invasive pulmonary aspergillosis complicating COVID-19 in the ICU -a case report Fatal invasive Aspergillosis and coronavirus disease in an immunocompetent patient Epidemiology of invasive pulmonary Aspergillosis among intubated patients with COVID-19: a prospective study Invasive pulmonary aspergillosis in severe COVID-19 pneumonia Invasive pulmonary Aspergillosis in patients with SARS-CoV-2 infection: a systematic review of the literature COVID-19 associated pulmonary Aspergillosis (CAPA)-from immunology to treatment Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature Important drug classes associated with potential drug-drug interactions in critically ill patients: highlights for cardiothoracic intensivists Broad spectrum triazoles for invasive mould infections in adults: Which drug and when? COVID-19-associated candidiasis (CAC): An underestimated complication in the absence of immunological predispositions? Candida auris: epidemiology, biology, antifungal resistance, and virulence Candida auris outbreak in a COVID-19 specialty care Unit -Florida First Candida auris outbreak during a COVID-19 pandemic in a tertiary-care center in Lebanon Emergence of Candida auris in Brazil in a COVID-19 intensive care unit Multidrugresistant Candida auris infections in critically Ill coronavirus disease patients Candida auris: a latent threat to critically Ill patients with coronavirus disease 2019 Outbreak of Candida auris infection in a COVID-19 hospital in Mexico Spread of carbapenem-resistant gram-negatives and Candida auris during the COVID-19 pandemic in critically Ill patients: One step back in antimicrobial Stewardship? Microorganisms PCR diagnosis of invasive candidiasis: systematic review and meta-analysis Falagas ME. β-D-Glucan assay for the diagnosis of invasive fungal infections: a meta-analysis Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium Global epidemiology of mucormycosis Epidemiology and diagnosis of mucormycosis: an update Epidemiology of systemic mycoses in the COVID-19 pandemic Epidemiology and diagnosis of mucormycosis: an update Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis Coronavirus disease (Covid-19) associated Mucormycosis (CAM): case report and systematic review of literature COVID-19 associated Mucormycosis presenting to the emergency department -an observational study of 70 patients Pulmonary cryptococcosis: a review of pathobiology and clinical aspects Cryptococcemia in a patient with COVID-19: a case report Cryptococcal meningitis: a review of cryptococcal antigen screening programs in Africa Atlas of infectious diseases: fungal infections. London: Current Medicine Group New approaches for Cryptococcosis treatment Disseminated cryptococcosis in a patient with metastatic prostate cancer who died in the coronavirus disease 2019 (COVID-19) outbreak Cryptococcus neoformans Meningoencephalitis in an immunocompetent patient after COVID-19 infection Cryptococcal meningoencephalitis during convalescence from severe COVID-19 pneumonia. The Neurohospitalist Detected SARS-CoV-2 in Ascitic fluid followed by cryptococcemia: a case report Autoimmune hemolytic anemia in a 24-year-old patient with COVID-19 complicated by secondary cryptococcemia and acute necrotizing encephalitis: a case report and review of literature Pneumocystis and severe acute respiratory syndrome coronavirus 2 coinfection: a case report and review of an emerging diagnostic dilemma. Open Forum Infect Dis Pneumocystis jirovecii pneumonia and severe acute respiratory syndrome coronavirus 2 coinfection in a patient with newly diagnosed HIV-1 infection Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19 COVID-19 and Pneumocystis jirovecii pulmonary coinfection-the first case confirmed through autopsy COVID-19 and Pneumocystis jirovecii pneumonia: back to the basics A case of COVID-19 and Pneumocystis jirovecii coinfection Coronavirus disease 2019 and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV The presence of Pneumocystis jirovecii in critically ill patients with COVID-19 Concurrent COVID-19 and Pneumocystis jirovecii pneumonia in a severely immunocompromised 25-year-old patient Pneumocystis jirovecii pneumonia and severe acute respiratory syndrome coronavirus 2 coinfection in a patient with newly diagnosed HIV-1 infection Co-infection with coronavirus disease 2019, previously undiagnosed human immunodeficiency virus, Pneumocystis jirovecii pneumonia and cytomegalovirus pneumonitis, with possible immune reconstitution inflammatory syndrome Narrative review of the relationship between COVID-19 and PJP: does it represent coinfection or colonization? Infection Pneumocystis jirovecii pneumonia as a sequela of COVID-19 An unusual case of severe Pneumocystis jirovecii pneumonia (pjp) presenting as "recurrent cytokine storm" following COVID-19 infection A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab Not COVID-19, don't overlook pneumocystis in patients on gefitinib! COVID-19 and Pneumocystis jirovecii pulmonary coinfection-the first case confirmed through autopsy Pneumocystis pneumonia, a COVID-19 mimic, reminds us of the importance of HIV testing in COVID-19 Pneumocystis jirovecii pneumonia mimicking COVID-19 pneumonia in a patient with newly diagnosed advanced HIV disease Pneumocystis pneumonia mimicking COVID-19 Nicht alles Milchglas ist COVID-19-Pneumocystis jirovecii-Pneumonie als Differenzialdiagnose Acute pulmonary histoplasmosis following COVID-19: novel laboratorial methods aiding diagnosis COVID-19-associated histoplasmosis in an AIDS patient Case report: incidental finding of COVID-19 infection after positron emission tomography/ CT imaging in a patient with a diagnosis of histoplasmosis and recurring fever Coronavirus disease 2019 (COVID-19) in a patient with disseminated histoplasmosis and HIV-a case report from argentina and literature review COVID-19 associated with AIDS-related disseminated histoplasmosis: a case report The coincidence of 2 epidemics, coccidioidomycosis and SARS-CoV-2: a case report The brief case: a fatal case of SARS-CoV-2 coinfection with coccidioides in texas-another challenge we face An acute pulmonary coccidioidomycosis coinfection in a patient presenting with multifocal pneumonia with COVID-19 COVID-19 and acute juvenile paracoccidioidomycosis coinfection Bacterial co-infections with SARS-CoV-2 Co-infections in people with COVID-19: a systematic review and meta-analysis Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. The Lancet Microbe Co-infection with respiratory pathogens among COVID-2019 cases Evaluation of bacterial co-infections of the respiratory tract in COVID-19 patients admitted to ICU The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling Tuberculosis: advances and challenges in development of new diagnostics and biomarkers Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases Association between tuberculosis and COVID-19 severity and mortality: a rapid systematic review and meta-analysis Case report: coronavirus disease and pulmonary tuberculosis in patients with human immunodeficiency virus: report of two cases COVID-19 in tuberculosis patients: a report of three cases Case report: COVID-19 recovery from triple infection with Mycobacterium tuberculosis, HIV, and SARS-CoV-2. The Am J Tro Med Hyg Tuberculosis and COVID-19 interaction: a review of biological, clinical and public health effects Impact of COVID-19 in patients with concurrent co-infections: a systematic review and metaanalyses Viral and atypical respiratory co-infections in COVID-19: a systematic review and meta-analysis Rates of coinfection between SARS-CoV-2 and other respiratory pathogens Influenza and COVID-19 coinfection: report of six cases and review of the literature Why the elderly appear to be more severely affected by COVID-19: the potential role of immunosenescence and CMV Are the healthy vulnerable? Cytomegalovirus seropositivity in healthy adults is associated with accelerated epigenetic age and immune-dysregulation Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments Cytomegalovirus treatment Infections, inflammation, and risk of neuropsychiatric disorders: the neglected role of "co-infection Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants SARS-CoV-2 infection and CMV dissemination in transplant recipients as a treatment for chagas cardiomyopathy: a case report A misleading CMV myocarditis during the COVID-19 pandemic: case report A new viral coinfection: SARS-CoV-2 pneumonia and cytomegalovirus pneumonitis in a renal transplant recipient Fatal cytomegalovirus pneumonia in a critically ill patient with COVID-19 Ganciclovir therapy for CMV viremia in a patient on VV ECMO with COVID-19 after treatment with tocilizumab Iranian kidney transplant recipients with COVID-19 infection: clinical outcomes and cytomegalovirus coinfection Herpes simplex virus infections. The Lancet Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients High rate of HSV-1 reactivation in invasively ventilated COVID-19 patients: Immunological findings Diagnosing herpes simplex-1 encephalitis at the time of COVID-19 pandemic SARS-CoV-2 infection (COVID-19) and herpes simplex virus-1 conjunctivitis: Concurrent viral infections or a cause-effect result? Herpes simplex keratitis in patients with SARS-CoV-2 Infection: a series of five cases Two fatal cases of acute liver failure due to HSV-1 infection in COVID-19 patients following immunomodulatory therapies Coinfection of human immunodeficiency virus, herpes simplex virus-2 and SARS-CoV-2 with false-negative real-time polymerase chain reaction Co-reactivation of the human herpesvirus alpha subfamily (herpes simplex virus-1 and varicella zoster virus) in a critically ill patient with COVID-19 Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients Interrogating the impact of intestinal parasite-microbiome on pathogenesis of COVID-19 in Sub-Saharan Africa Intestinal parasitic infections in different groups of immunocompromised patients in Kashan and Qom cities, central Iran Latent toxoplasmosis and human Neglected risk factors for HIV and Toxoplasma gondii co-infection. The lancet HIV Parasitic encephalitis in immunocompetent individuals Toxoplasmosis among patients with immunocompromising conditions: a snapshot Serological and molecular survey of toxoplasmosis in renal transplant recipients and hemodialysis patients in Kashan and Qom regions, central Iran Ocular toxoplasmosis in an adult receiving long-term corticosteroid therapy Reactivation of latent toxoplasmosis following dexamethasone implant injection Tugal-Tutkun I. Fulminant ocular toxoplasmosis: the hazards of corticosteroid monotherapy Cerebral toxoplasmosis in systemic lupus erythematosus following intravenous methylprednisolone Cerebral toxoplasmosis: case report Cerebral toxoplasmosis after rituximab therapy Bilateral toxoplasmosis retinitis associated with ruxolitinib Incidence of toxoplasma retinochoroiditis in patients with ankylosing spondylitis after using TNF-α blockers Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis Cerebral toxoplasmosis in a rheumatoid arthritis patient on immunosuppressive therapy Toxoplasmosis in a patient receiving ixekizumab for psoriasis Toxoplasma gondii as a possible risk factor for COVID-19 severity: a case-control study The symptoms and clinical manifestations observed in COVID-19 patients/long COVID-19 symptoms that parallel toxoplasma gondii infections Helminth infections and immunosenescence: the friend of my enemy Are pregnant women with chronic helminth infections more susceptible to congenital infections? Front Immunol Helminths and COVID-19 co-infections: a neglected critical challenge Emerging issues in COVID-19 vaccination in tropical areas: impact of the immune response against helminths in endemic areas COVID-19 and helminth infection: beyond the Th1/Th2 paradigm Morbidity associated with chronic Strongyloides stercoralis infection: a systematic review and meta-analysis Severe strongyloidiasis: a systematic review of case reports COVID-19 and dexamethasone: a potential strategy to avoid steroid-related strongyloides hyperinfection Case report: disseminated strongyloidiasis in a patient with COVID-19 Strongyloides infection manifested during immunosuppressive therapy for SARS-CoV-2 pneumonia The prevalence of opportunistic infections and malignancies in autopsied patients with human immunodeficiency virus infection in Japan Opportunistic infections in patients with cancer Screening of toxoplasmosis in cancer patients: a concern A review of critical periods for opportunistic infection in the new transplantation era Progress in diagnosis of opportunistic infections in HIV/AIDS COVID-19 and multiorgan failure: A narrative review on potential mechanisms The immune system and COVID-19: Friend or foe? Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial Efficacy of tocilizumab in COVID-19: a systematic review and meta-analysis Tocilizumab in patients hospitalized with Covid-19 pneumonia Efficacy of tocilizumab in patients hospitalized with covid-19 The role of interleukin 6 during viral infections. Front Microbiol IL-6 inhibition in critically Ill COVID-19 patients is associated with increased secondary infections Cryptococcal meningitis: case report Recurrent allergic bronchopulmonary aspergillosis in a patient with rheumatoid arthritis treated with etanercept and tocilizumab Cytomegalovirus viremia, pneumonitis, and tocilizumab therapy Tuberculosis sepsis after tocilizumab treatment The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study Use of Baricitinib in patients with moderate and severe COVID-19 Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19 Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series Infliximab and intravenous gammaglobulin in hospitalized severe COVID-19 patients in intensive care unit Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Anakinra for severe forms of COVID-19: a cohort study Canakinumab in a subgroup of patients with COVID-19 Canakinumab to reduce deterioration of cardiac and respiratory function in SARS-CoV-2 associated myocardial injury with heightened inflammation (canakinumab in Covid-19 cardiac injury: the three C study) GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. The Lancet Rheumatol Misdiagnosis in the COVID-19 Era: when zebras are everywhere, don't forget the horses The combination of sulfamethoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resistance in Mycobacterium tuberculosis Tuberculosis and trimethoprim-sulfamethoxazole Drug interactions: a review of the unseen danger of experimental COVID-19 therapies COVID-19 drug interactions Tocilizumab for treatment of patients with severe COVID-19: a retrospective cohort study Primary cutaneous cryptococcosis and secondary antigenemia in a patient with long-term corticosteroid therapy Peetermans WE. Cutaneous cryptococcosis in corticosteroid-treated patients without aids Cryptococcal meningitis as a complication of systemic lupus erythematosus treated with systemic corticosteroids Solitary pelvic ectopic kidney and limb anomalies: rare variant of acrorenal syndrome Disseminated cryptococcosis in a patient with multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone Disseminated cryptococcosis complicated with bilateral pleural effusion and ascites during corticosteroid therapy for organizing pneumonia with myelodysplastic syndrome Pneumocystis pneumonia in patients treated with long-term steroid therapy for symptom palliation: a neglected infection in palliative care. The Am J Hospice Palliative Care Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies Invasive Aspergillosis in renal transplant recipients: correlation with corticosteroid therapy Corticosteroid treatment as a risk factor for invasive aspergillosis in patients with lung disease Fatal aspergillosis in a patient with SARS who was treated with corticosteroids Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone Esophageal candidiasis as a complication of inhaled corticosteroids Disseminated candidal infections and intravenous hydrocortisone in preterm infants A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient Pulmonary mucormycosis in a patient with acute liver failure: a case report and systematic review of the literature Surgical emergencies confounded by H1N1 influenza infection -a plea for concern Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy Invasive mucormycosis of the maxillary sinus: extensive destruction with an indolent presentation Fatal strongyloidiasis in patients receiving corticosteroids Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review Severe strongyloidiasis in corticosteroid-treated patients Fatal Strongyloidiasis following corticosteroid therapy Disseminated strongyloidiasis with cerebral involvement: a complication of corticosteroid therapy Disseminated strongyloidiasis arising from a single dose of dexamethasone before stereotactic radiosurgery Pulmonary strongyloidiasis complicating therapy with corticosteroids Strongyloides stercoralis hyperinfection after corticosteroid therapy: a report of two cases Inhaled corticosteroids and risk of tuberculosis in patients with obstructive lung diseases: a systematic review and meta-analysis of non-randomized studies Cytomegalovirus reactivation after low-dose steroid treatment for hemolytic anemia in a patient with primary Epstein-Barr virus infection Active infection with cytomegalovirus and herpes group viruses in children receiving corticosteroid therapy Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis An opportunistic infection associated with Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor Pulmonary cryptococcosis in the setting of tofacitinib therapy for psoriasis Cryptococcal meningoencephalitis associated with the long-term use of ruxolitinib A case report of cryptococcal meningitis associated with ruxolitinib Invasive aspergillosis manifesting as retinal necrosis in a patient treated with ruxolitinib Ruxolitinib-associated tuberculosis-a rare complication of a novel drug Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis; case series & literature review Reactivation of a common infection following treatment with a novel agent for an uncommon disease-ruxolitinib associated tuberculosis: two cases Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy A case report of locally invasive Aspergillus fumigatus infection in a patient on canakinumab Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet Cockatiel Asymptomatic pulmonary cryptococcosis in a patient with Crohn's disease on infliximab: case report Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab Disseminated Cryptococcus neoformans after treatment with infliximab for rheumatoid arthritis Cryptococcal meningitis in a patient treated with infliximab Cryptococcal meningitis in a patient treated with infliximab and mycophenolate mofetil for Behcet's disease Primary cutaneous cryptococcosis during infliximab therapy Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases Pneumocystis Jiroveci (Carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient With Crohn's disease Pneumocystis jiroveci pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, antitumor necrosis factor α neutralizing antibody Pneumocystis pneumonia associated with infliximab in Japan Allergic bronchopulmonary aspergillosis after infliximab therapy for sarcoidosis: a potential mechanism related to T-helper cytokine balance Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: A possible healthcare-associated case? Implications of endodontic-related sinus aspergillosis in a patient treated by infliximab: a case report Invasive central nervous system aspergillosis in a patient with Crohn's disease after treatment with infliximab and corticosteroids Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature Systemic candidiasis and infliximab therapy Fungal arthritis of the wrist caused by Candida parapsilosis during infliximab therapy for rheumatoid arthritis Pneumocystis carinii pneumonia with oral candidiasis after infliximab therapy for Crohn's disease Cutaneous mucormycosis complicating methotrexate, prednisone, and infliximab therapy Mucormycosis in a patient with low risk myelodysplasia treated with anti-TNF-alpha Mucormycosis in a Crohn's disease patient treated with infliximab Pulmonary mucormycosis in a patient with crohn disease on immunosuppressive medications including infliximab Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-α therapy Infliximab-induced tuberculosis in patients with UC: experience from India-a country with high prevalence of tuberculosis Risk of tuberculosis during infliximab therapy for inflammatory bowel disease, rheumatoid arthritis, and spondyloarthropathy: a meta-analysis High risk of tuberculosis during infliximab therapy despite tuberculosis screening in inflammatory bowel disease patients in India Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy The authors would like to apologize from authors whose works have not cited in this article because of space limitations.Authors' contributions AA conceived the article. AA, SF, and AK analyzed the references. AA, SF, and AK wrote the draft of manuscript. All authors revised the initial manuscript and approved its final version.Funding None. The authors declare that they have no competing interests.